Panbela Therapeutics (PBLA) Competitors $0.16 0.00 (0.00%) As of 08/15/2025 10:50 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PBLA vs. SPRC, CERO, ENVB, LIPO, PCSA, PWUP, RDHL, PBM, PRFX, and GLMDShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include SciSparc (SPRC), CERo Therapeutics (CERO), Enveric Biosciences (ENVB), Lipella Pharmaceuticals (LIPO), Heatwurx (PCSA), PowerUp Acquisition (PWUP), Redhill Biopharma (RDHL), Psyence Biomedical (PBM), PainReform (PRFX), and Galmed Pharmaceuticals (GLMD). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Its Competitors SciSparc CERo Therapeutics Enveric Biosciences Lipella Pharmaceuticals Heatwurx PowerUp Acquisition Redhill Biopharma Psyence Biomedical PainReform Galmed Pharmaceuticals Panbela Therapeutics (NASDAQ:PBLA) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk. Which has higher valuation and earnings, PBLA or SPRC? SciSparc has higher revenue and earnings than Panbela Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPanbela TherapeuticsN/AN/A-$25.26M-$71.130.00SciSparc$1.31M1.82-$6.28MN/AN/A Does the media prefer PBLA or SPRC? In the previous week, Panbela Therapeutics and Panbela Therapeutics both had 1 articles in the media. SciSparc's average media sentiment score of 1.08 beat Panbela Therapeutics' score of 1.00 indicating that SciSparc is being referred to more favorably in the news media. Company Overall Sentiment Panbela Therapeutics Positive SciSparc Positive Which has more risk and volatility, PBLA or SPRC? Panbela Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, SciSparc has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Do insiders and institutionals have more ownership in PBLA or SPRC? 4.4% of Panbela Therapeutics shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 0.0% of Panbela Therapeutics shares are held by insiders. Comparatively, 1.5% of SciSparc shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is PBLA or SPRC more profitable? Company Net Margins Return on Equity Return on Assets Panbela TherapeuticsN/A N/A -302.61% SciSparc N/A N/A N/A SummarySciSparc beats Panbela Therapeutics on 6 of the 7 factors compared between the two stocks. Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$767K$852.33M$5.67B$9.83BDividend YieldN/A4.84%3.79%4.08%P/E Ratio0.001.1930.5825.12Price / SalesN/A26.45463.49115.90Price / CashN/A19.5637.4059.05Price / Book-0.016.589.096.18Net Income-$25.26M-$4.98M$3.25B$264.89M7 Day PerformanceN/A3.15%7.42%4.22%1 Month Performance-32.87%2.26%5.49%2.02%1 Year Performance-57.21%14.15%30.67%24.22% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela Therapeutics1.1224 of 5 stars$0.16flatN/A-57.3%$767KN/A0.006Short Interest ↓SPRCSciSparc1.0062 of 5 stars$5.69-5.0%N/A-46.2%$3.04M$1.31M0.004CEROCERo Therapeutics3.2895 of 5 stars$7.73+1.2%$45.00+482.1%-97.3%$3.02MN/A0.008Short Interest ↑ENVBEnveric Biosciences2.8265 of 5 stars$1.21+5.2%$10.00+726.4%-84.8%$2.99MN/A-0.0320News CoverageEarnings ReportLIPOLipella PharmaceuticalsN/A$0.65-3.2%N/A-81.2%$2.90M$536.36K-0.164PCSAHeatwurx3.2709 of 5 stars$0.24+4.8%$2.00+726.4%-83.5%$2.88MN/A-0.0820News CoveragePositive NewsShort Interest ↓PWUPPowerUp AcquisitionN/A$0.36+1.2%N/A-96.6%$2.83MN/A0.00N/AGap UpHigh Trading VolumeRDHLRedhill BiopharmaN/A$1.23+2.1%N/A-99.4%$2.82M$8.04M0.00210News CoverageShort Interest ↑PBMPsyence Biomedical2.2716 of 5 stars$4.95+9.0%N/A-99.0%$2.82MN/A0.00N/APositive NewsShort Interest ↓Gap DownHigh Trading VolumePRFXPainReform1.2442 of 5 stars$1.35-0.2%N/A+8.4%$2.71MN/A-0.014News CoverageUpcoming EarningsGLMDGalmed Pharmaceuticals1.9458 of 5 stars$1.60-1.8%N/A-60.0%$2.64MN/A-0.1020News CoverageShort Interest ↓Gap Up Related Companies and Tools Related Companies SciSparc Competitors CERo Therapeutics Competitors Enveric Biosciences Competitors Lipella Pharmaceuticals Competitors Heatwurx Competitors PowerUp Acquisition Competitors Redhill Biopharma Competitors Psyence Biomedical Competitors PainReform Competitors Galmed Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBLA) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access